Endocrine Cancer

Postoperative Radioactive Iodine Ablation Effective in Reducing Disease Recurrence in Low-Risk Thyroid Cancer

Postoperative Radioactive Iodine Ablation Effective in Reducing Disease Recurrence in Low-Risk Thyroid Cancer

For patients with low-risk thyroid cancer, ablation when indicated could be achieved with 1.1 GBq radioactive iodine after recombinant human thyroid-stimulating hormone (rhTSH) injections, as this combination reduces whole body irradiation and maintains quality of life.

<i>ARID1A</i> Mutations Might Predict Tumor Response to Immunotherapy

ARID1A Mutations Might Predict Tumor Response to Immunotherapy

By

New findings bolster the case for the predictive utility of ARID1A mutations.

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

By

A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

By

Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

By

Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.

Chemoradiotherapy Before Surgery May Improve Outcomes in Resectable Pancreatic Cancer

Chemoradiotherapy Before Surgery May Improve Outcomes in Resectable Pancreatic Cancer

By

Evidence suggests that neoadjuvant chemoradiotherapy may afford benefit, but this hypothesis requires further validation.

mFOLFIRINOX After Resection May Lead to Improved Outcomes in Pancreatic Carcinoma

mFOLFIRINOX After Resection May Lead to Improved Outcomes in Pancreatic Carcinoma

By

Previous studies demonstrated that FOLFIRINOX is more effective than gemcitabine as first-line treatment for patients with metastatic pancreatic cancer with good performance status.

Can Oncolytic Viruses Improve Immunotherapies?

Can Oncolytic Viruses Improve Immunotherapies?

By

Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.

Clonally Transmissible Cancers in Nature

Clonally Transmissible Cancers in Nature

By

While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.

Insulin Pen Devices

Insulin Pen Devices comparison chart for patients with diabetes mellitus.

Preoperative Chemotherapy May Improve Margin-negative Resection Rates, Survival Outcomes in Pancreatic Cancer

Preoperative Chemotherapy May Improve Margin-negative Resection Rates, Survival Outcomes in Pancreatic Cancer

By

Researchers enrolled 50 previously untreated patients with newly diagnosed and borderline resectable pancreatic cancer.

Insulin Products

Insulin products table with pharmacokinetic properties.

The Hunt for Effective Anticancer Vaccines

The Hunt for Effective Anticancer Vaccines

By

Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.

Pancreatic Cancer and the Microbiome — In the Clinic

Pancreatic Cancer and the Microbiome — In the Clinic

By

In the future, targets of drug development may be within the microbiome.

HIV-Associated Cancers: A Paradigm Shift?

HIV-Associated Cancers: A Paradigm Shift?

By

Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.

Neoadjuvant Chemotherapy May Confer Benefit in Pancreatic Adenocarcinoma

Neoadjuvant Chemotherapy May Confer Benefit in Pancreatic Adenocarcinoma

By

The addition of preoperative chemotherapy may eradicate micrometastatic disease and direct postoperative therapy in the case of resistance.

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

By

Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.

Phase 1 Trials: Therapy, Not Just Science

Phase 1 Trials: Therapy, Not Just Science

By

Phase 1 trials should be considered therapeutic options for some patients.

Immunotherapy and the Risk of Myocarditis

Immunotherapy and the Risk of Myocarditis

By

The risk should not discourage patients with cancer from taking these potentially life-extending therapies.

Can A Consortium of Hospitals Help To Reduce Drug Prices?

Can A Consortium of Hospitals Help To Reduce Drug Prices?

By

To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.

Larotrectinib: Promising for All TRK-Positive Tumors

Larotrectinib: Promising for All TRK-Positive Tumors

By

Larotrectinib may have durable antitumor activity in patients with TRK fusion-positive cancers, regardless of tumor type.

Diagnosing Medicine's Intractable Gender Pay Gap

Diagnosing Medicine's Intractable Gender Pay Gap

By

The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exception.

Managing Adverse Events in the Era of Immunotherapy

Managing Adverse Events in the Era of Immunotherapy

By

The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.

Healthful Lifestyles and Cancer: Much More Than A Single Behavior

Healthful Lifestyles and Cancer: Much More Than A Single Behavior

By

A recent study is the first to demonstrate the cumulative effect of a large number of lifestyle behaviors.

Cancer Immunosurveillance Comes of Age

Cancer Immunosurveillance Comes of Age

By

As oncologists learn to target the immune response to "self and non-self," a delicate therapy balance will eventually be achieved with predictable outcomes, benefits, and toxicity in the fight against cancer.

Thymomas and Thymic Carcinomas Treatment Regimens

Thymomas and Thymic Carcinomas Treatment Regimens

Find current treatment regimens for rare thymomas and thymic carcinomas, including options such as carboplatin + paclitaxel and more.

FDA Approves Lutetium Lu 177 Dotatate for Gastroenteropancreatic Neuroendocrine Tumors

FDA Approves Lutetium Lu 177 Dotatate for Gastroenteropancreatic Neuroendocrine Tumors

By

Lutetium Lu 177 dotatate binds to somatostatin receptors to deliver radiation directly into tumor cells.

Thymic Carcinoma: Pembrolizumab May Be An Effective Option

Thymic Carcinoma: Pembrolizumab May Be An Effective Option

By

Thymic carcinomas typically express high levels of PD-L1, leading researchers to predict a positive response to pembrolizumab.

Pancreatitis and the Risk of Cancer

Pancreatitis and the Risk of Cancer

By

Some patients diagnosed with HP or AP have a significantly increased risk of developing pancreatic cancer.

Does Immune Checkpoint Inhibition Have A Dark Side?

Does Immune Checkpoint Inhibition Have A Dark Side?

By

Careful research is needed to ensure that immunotherapies activating T cells do not inadvertently fuel progression of T cell malignancies.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs